215 related articles for article (PubMed ID: 37708365)
1. Comparative Effectiveness of Therapeutic Interventions in Pregnancy and Lactation-Associated Osteoporosis: A Systematic Review and Meta-analysis.
Anagnostis P; Lampropoulou-Adamidou K; Bosdou JK; Trovas G; Galanis P; Chronopoulos E; Goulis DG; Tournis S
J Clin Endocrinol Metab; 2024 Feb; 109(3):879-901. PubMed ID: 37708365
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and bisphosphonates treatment of rare pregnancy- and lactation-associated osteoporosis.
Li LJ; Zhang J; Gao P; Lv F; Song YW; Chang XY; Zhao DC; Wang O; Jiang Y; Xing XP; Xia WB; Li M
Clin Rheumatol; 2018 Nov; 37(11):3141-3150. PubMed ID: 29946989
[TBL] [Abstract][Full Text] [Related]
3. Bone Density After Teriparatide Discontinuation With or Without Antiresorptive Therapy in Pregnancy- and Lactation-Associated Osteoporosis.
Lee S; Hong N; Kim KJ; Park CH; Lee J; Rhee Y
Calcif Tissue Int; 2021 Nov; 109(5):544-553. PubMed ID: 34037833
[TBL] [Abstract][Full Text] [Related]
4. Effect of teriparatide on pregnancy and lactation-associated osteoporosis with multiple vertebral fractures.
Choe EY; Song JE; Park KH; Seok H; Lee EJ; Lim SK; Rhee Y
J Bone Miner Metab; 2012 Sep; 30(5):596-601. PubMed ID: 22105654
[TBL] [Abstract][Full Text] [Related]
5. Skeletal response to treatment with teriparatide (TPD) after bisphosphonate in post-menopausal women with osteoporosis and a high prevalence of secondary risk factors in real-life setting of a metabolic bone clinic; effect of age and vitamin D status.
Mok J; Brown C; Moore AEB; Min SS; Hampson G
Endocr Res; 2018 Aug; 43(3):195-202. PubMed ID: 29652557
[TBL] [Abstract][Full Text] [Related]
6. Pregnancy and Lactation-Associated Osteoporosis Successfully Treated with Romosozumab: A Case Report.
Kaneuchi Y; Iwabuchi M; Hakozaki M; Yamada H; Konno SI
Medicina (Kaunas); 2022 Dec; 59(1):. PubMed ID: 36676643
[TBL] [Abstract][Full Text] [Related]
7. Switching to Denosumab or Bisphosphonates After Completion of Teriparatide Treatment in Women With Severe Postmenopausal Osteoporosis.
Kocjan T; Rajic AS; Janez A; Vidmar G; Orehek N; Marc J; Ostanek B
Endocr Pract; 2021 Sep; 27(9):941-947. PubMed ID: 34111556
[TBL] [Abstract][Full Text] [Related]
8. Head-to-head comparisons of bisphosphonates and teriparatide in osteoporosis: a meta-analysis.
Liu CL; Lee HC; Chen CC; Cho DY
Clin Invest Med; 2017 Jun; 40(3):E146-E157. PubMed ID: 28653616
[TBL] [Abstract][Full Text] [Related]
9. Teriparatide Treatment in Patients with Pregnancy- and Lactation-Associated Osteoporosis.
Lampropoulou-Adamidou K; Trovas G; Triantafyllopoulos IK; Yavropoulou MP; Anastasilakis AD; Anagnostis P; Toulis KA; Makris K; Gazi S; Balanika A; Tournis S
Calcif Tissue Int; 2021 Nov; 109(5):554-562. PubMed ID: 34132853
[TBL] [Abstract][Full Text] [Related]
10. Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study.
Senn C; Günther B; Popp AW; Perrelet R; Hans D; Lippuner K
Osteoporos Int; 2014 Jul; 25(7):1945-51. PubMed ID: 24760244
[TBL] [Abstract][Full Text] [Related]
11. Case report: Teriparatide treatment in a case of severe pregnancy -and lactation- associated osteoporosis.
Lampropoulou-Adamidou K; Trovas G; Stathopoulos IP; Papaioannou NA
Hormones (Athens); 2012; 11(4):495-500. PubMed ID: 23422774
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.
Hernandez AV; Pérez-López FR; Piscoya A; Pasupuleti V; Roman YM; Thota P; Herrera A
Maturitas; 2019 Nov; 129():12-22. PubMed ID: 31547908
[TBL] [Abstract][Full Text] [Related]
13. Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis: A meta-analysis.
Yuan F; Peng W; Yang C; Zheng J
Int J Surg; 2019 Jun; 66():1-11. PubMed ID: 30890377
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use.
Lyu H; Zhao SS; Yoshida K; Tedeschi SK; Xu C; Nigwekar SU; Leder BZ; Solomon DH
J Clin Endocrinol Metab; 2019 Nov; 104(11):5611-5620. PubMed ID: 31265071
[TBL] [Abstract][Full Text] [Related]
15. Changes in bone mineral density and bone turnover markers during treatment with teriparatide in pregnancy- and lactation-associated osteoporosis.
Hong N; Kim JE; Lee SJ; Kim SH; Rhee Y
Clin Endocrinol (Oxf); 2018 May; 88(5):652-658. PubMed ID: 29389010
[TBL] [Abstract][Full Text] [Related]
16. Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial.
Sugimoto T; Shiraki M; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Kuroda T; Nakamura T
Curr Med Res Opin; 2013 Mar; 29(3):195-203. PubMed ID: 23259702
[TBL] [Abstract][Full Text] [Related]
17. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis.
Devogelaer JP; Adler RA; Recknor C; See K; Warner MR; Wong M; Krohn K
J Rheumatol; 2010 Jan; 37(1):141-8. PubMed ID: 19918047
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates for steroid-induced osteoporosis.
Allen CS; Yeung JH; Vandermeer B; Homik J
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD001347. PubMed ID: 27706804
[TBL] [Abstract][Full Text] [Related]
19. Treatment for osteoporosis in people with ß-thalassaemia.
Bhardwaj A; Swe KM; Sinha NK; Osunkwo I
Cochrane Database Syst Rev; 2016 Mar; 3():CD010429. PubMed ID: 26964506
[TBL] [Abstract][Full Text] [Related]
20. Comparison between teriparatide and bisphosphonates for improving bone mineral density in postmenopausal osteoporosis patients: A meta-analysis.
Fan G; Zhao Q; Lu P; Chen H; Tan W; Guo W; Liu C; Liu J
Medicine (Baltimore); 2020 Apr; 99(15):e18964. PubMed ID: 32282692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
